June 2025 saw significant FDA activity including approvals for Gilead’s twice-yearly HIV preventive shot and Nuvation Bio’s ROS1 inhibitor for lung cancer, reflecting continued innovation in infectious disease and oncology treatments. Arvinas and Pfizer filed for estrogen receptor PROTAC approval, expanding options for hormone-driven cancers. Novo Nordisk and Altimmune reported early clinical trial results advancing obesity and metabolic disease therapeutics. Meanwhile, BRIS and GSK drugs experienced mixed clinical results, underscoring the complex developmental landscape.